Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
<p>Abstract</p> <p>Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular (CV) disease; however, conclusive evidence that glycemic control leads to improved cardiovascular outcomes is lacking. Saxagliptin is a potent, selective dipeptidyl peptidase-4 inhi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-01-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | http://www.cardiab.com/content/11/1/6 |